NYSE$INSP

Inspire Medical Systems Inc. · Q3 2025 earnings

Q3 2025 earnings · · After market close · Investor relations

Briefing

Inspire Medical Systems reported Q3 2025, revenue of $224.5M, net income of $9.9M.

For Q3 2025, Inspire Medical Systems reported revenue of $224.5M, net income of $9.9M. Management discusses operations, liquidity, and outlook in the quarterly filing.

  • Revenue $224.5M.
  • Net income $9.9M.
  • Inspire Medical Systems highlights liquidity, operations, and sector risks in MD&A.

Headline financials

Total Revenue

$225M

Previous: $203M+10.5%
EPS (adj)

$0.38

Previous: $0.60-36.7%
Gross Margin

85.8%

Previous: 84.1%+2.0%
Operating Cash Flow

$68.5M

No prior period
Adjusted EBITDA

$44M

Previous: $44.5M-1.1%
Adjusted EBITDA Margin

20.0%

Previous: 22.0%-9.1%
Capital Expenditures

-$27.8M

Previous: -$32.1M+13.3%
Net Income

$9.93M

Previous: $18.5M-46.3%
Operating Income

$9.64M

Previous: $14.3M-32.6%
Gross Profit

$193M

Previous: $171M+12.8%

Revenue & EPS history

Inspire · Revenue · Quarterly

$225M

Q3 2025+10.5%vs Q3 2024
Beat estimate in 15 of 15 quarters(100%)
ActualEstimate

Forward guidance

The filing discusses Inspire Medical Systems's outlook, including capital allocation, operating priorities, and market risks relevant to the reported quarter.

Tailwinds

  • Inspire Medical Systems cites operational priorities and demand trends supporting the outlook.
  • Balance sheet and liquidity actions aim to fund growth and returns.

Headwinds

  • Macro, pricing, and input-cost volatility could pressure margins.
  • Segment mix and one-time items may affect quarter-to-quarter comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

+2.4%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+3.3%

Avg return

30 days after

69%

22 / 32 earnings

Positive

+34.4%

Q3 2020

Best reaction

-34.9%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-12.2%-19.2%-23.1%
Q4 2025-12.5%-11.5%-14.1%
Q3 2025+15.6%+11.0%+90.0%
Q1 2025+1.6%-4.7%-14.4%
Q4 2024+1.7%+2.6%-12.2%
Q3 2024+4.3%+3.1%+3.3%
Q2 2024+29.5%+32.8%+35.6%
Q1 2024-34.9%-33.1%-37.7%
Q4 2023-6.5%-9.8%-4.8%
Q3 2023-20.9%-23.5%-2.1%
Q2 2023-3.5%-3.7%-21.2%
Q1 2023+5.0%+5.8%+15.3%
Q4 2022+9.7%+7.9%-0.4%
Q3 2022+6.0%+6.4%+22.9%
Q2 2022+4.4%+4.0%-11.0%
Q1 2022-4.5%-19.8%-14.4%
Q4 2021+5.4%+0.6%-1.4%
Q3 2021+1.3%+4.1%-16.0%
Q2 2021+12.9%+14.4%+26.1%
Q1 2021-16.0%-17.4%-29.6%
Q4 2020+3.4%+4.1%-11.4%
Q3 2020+34.4%+40.7%+60.3%
Q2 2020+7.4%+3.5%+17.9%
Q1 2020+3.7%+6.2%+26.1%
Q4 2019+6.4%+7.7%-27.2%
Q3 2019+4.3%+4.8%+21.7%
Q2 2019+4.5%+1.9%+7.3%
Q1 2019-2.5%-5.7%-0.6%
Q4 2018+5.4%+5.0%-4.5%
Q3 2018+15.4%+1.8%-9.9%
Q2 2018-1.8%-0.1%+15.6%
Q1 2018+10.0%+6.4%+20.5%
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro